LDS/Medical Tests/Fluphenazine, Serum

Fluphenazine, Serum

Fluphenazine is an antipsychotic compound that is used to treat schizophrenia. Fluphenazine belongs to the class of compounds known as phenothiazines. Schizophrenia is the main disorder that employs the use of antipsychotics for patient treatment.

Fluphenazine is metabolized in the liver by the cytochrome 450 system, and reaches steady state plasma concentrations in 2-10 days. Fluphenazine is rapidly absorbed following an oral or IM dose. The half-life of fluphenazine is approximately 13-33 hours or up to 9 days with the decanoate formulation.

The adverse effects of this class of medications varies from mild to life-threatening depending on abuse. In general the adverse effects of these drugs are primarily non-neurologic in low doses and neurologic in high doses.

  • Therapeutic monitoring
  • Drug abuse evaluation
  • Toxicity assessment
  • Patient Compliance
A qualitative positive result from an immunoassay type test indicates only the presence of antipsychotics and does not necessarily correlate with the extent of physiological and psychological effects. Any positive result should be confirmed by a non-immunological method such as GC, LC/MS or GC/MS.

Therapeutic levels; low dose: 0.5-2.5 ng/mL: high dose - 5-20 ng/mL

Toxic levels: > 40 ng/mL

Note: therapeutic ranges and toxic thresholds are best evaluated from blood samples. Quantitative results obtained with blood samples collected at specific times after drug administration are preferred for pharmacokinetic analyses.    

   

Cut-Off Ranges

Cut-off values can vary based on the particular method of analysis that is used for detection by a quantitative method, such as LC/MS or GC/MS. The testing laboratory cut-off range is listed on the patient report. Consult your physician for further information or click on one of the references that are listed below.

Liquid Chromatography/Mass Spectroscopy (LC/MS) or Gas Chromatography/Mass Spectroscopy (GC/MS). The preferred method of detection is LC/MS. The main method of quantitation detection is via LC/MS or LC/MS/MS (liquid chromatography coupled with mass spectroscopy). This particular method of analysis is used to detect fluphenazine and metabolites. fluphenazine can be separated from biological specimens by liquid-liquid extraction or by solid-phase extraction. When analyzing urine specimens, a hydrolysis step is required to free the parent drug and metabolites from glucuronide conjugates. Enzymatic hydrolysis is preferred over acid hydrolysis.

Serum specimens that are collected in a non-gel red top tube are the preferred specimens of choice. Plasma specimens are acceptable if drawn in a heparin (green top) tube. Specimens should be spun and the serum or plasma separated and refrigerated.

Stability

  • Ambient: 3-5 days
  • Refrigerated: 5-7 days
  • Frozen: 30 days
Pharmacogenetic testing such as genotyping for *CYP3A4, CYP3A5, CYP2D6, CYP2C9, CYP2C19,* COMT and *OPRM1* variants could guide drug and dose selection. Supportive testing such as a liver profile, kidney profile, comprehensive metabolic panel, CBC, and testing for concomitant drugs may be appropriate.
1-3 days.
Please log in to view content.
Create an account to get a 30-day free trial.
Login
Please log in to view content.
Create an account to get a 30-day free trial.
Login
Please log in to view content.
Create an account to get a 30-day free trial.
Login
  • Basalt RC (ed). Disposition of toxic drugs and chemicals in man, 7th ed. Foster City, CA: Biomedical Publications; 2004.
  • Bell J. Methods for monitoring neuroleptic drugs. AACC Therapeutic Drug Monitoring and Toxicology. 1985;6:1-6.
  • Levine B (ed). Principles of Forensic Toxicology, 4th ed. Washington DC: AACC Press. Chapter 24, Therapeutic Drugs III: Neuroleptics (Antipsychotics), 421-434; 2013.
  • Balant-Gorgia A.E., Balant LP. Therapeutic drug monitoring of antidepressants. Clin Thera, 1992;14(4):612-4.
  • Baselt RC (ed). Analytical procedures for therapeutic drug monitoring and emergency toxicology, 2nd ed. Littleton, MA: PSG Publishing Co.; 1987.
  • Baselt RC (ed). Disposition of toxic drugs and chemicals in man, 6th ed. Foster City, CA: Biomedical Publications; 2002.
  • Fitzgerald R. Analytical toxicology of the benzodiazepines. AACC Therapeutic Drug Monitoring and Toxicology. 1995;16(7):169-79.
  • Harman JG, Limbird LE, Molinoff PB, Ruddon RW, Gilman AG (eds). Goodman and Gilman’s the pharmacological basis of therapeutics, 9th ed. New York: McGraw-Hill Co.; 1996.
  • Wians FH. Benzodiazepine update. AACC Therapeutic Drug Monitoring and Toxicology. 1989;11(4):7-20.
  • Zherdev VP, Caccia S, Garattini S, Ekonomov AL. Species differences in phenazepam kinetics and metabolism. Euro J Drug Metab Pharm. 1982;7:191-6.